Announcement • Jun 30
APT Medical Inc. to Report First Half, 2026 Results on Aug 20, 2026 APT Medical Inc. announced that they will report first half, 2026 results on Aug 20, 2026 Announcement • May 12
APT Medical Inc. (SHSE:688617) announces an Equity Buyback for CNY 100 million worth of its shares. APT Medical Inc. (SHSE:688617) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of class A shares. The shares will be repurchased at a price of not more than CNY 315 per share. The shares purchased will be used for the company's ESOP or equity incentives. Shares not used within 3 years after the completion of the repurchase will be cancelled. The program will be funded out of the company's self-owned funds. The program will be valid till 10 months from directorate's approval. Price Target Changed • Apr 28
Price target decreased by 7.3% to CN¥335 Down from CN¥362, the current price target is an average from 7 analysts. New target price is 38% above last closing price of CN¥243. Stock is down 17% over the past year. The company is forecast to post earnings per share of CN¥7.39 for next year compared to CN¥5.82 last year. Reported Earnings • Apr 24
First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2026 results: EPS: CN¥1.64 (up from CN¥1.30 in 1Q 2025). Revenue: CN¥704.1m (up 25% from 1Q 2025). Net income: CN¥229.4m (up 25% from 1Q 2025). Profit margin: 33% (in line with 1Q 2025). Revenue missed analyst estimates by 2.0%. Earnings per share (EPS) exceeded analyst estimates by 4.7%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Apr 21
Now 21% undervalued Over the last 90 days, the stock has risen 4.6% to CN¥252. The fair value is estimated to be CN¥318, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 25%. For the next 3 years, revenue is forecast to grow by 22% per annum. Earnings are also forecast to grow by 23% per annum over the same time period. Announcement • Mar 30
APT Medical Inc. to Report Q1, 2026 Results on Apr 24, 2026 APT Medical Inc. announced that they will report Q1, 2026 results on Apr 24, 2026 New Risk • Mar 26
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Announcement • Mar 24
APT Medical Inc., Annual General Meeting, Apr 14, 2026 APT Medical Inc., Annual General Meeting, Apr 14, 2026, at 13:30 China Standard Time. Location: No. 009, Xiangxiang Avenue, Xiangxiang Economic Development Zone, Xiangxiang, Hunan China Reported Earnings • Feb 27
Full year 2025 earnings released: EPS: CN¥5.82 (vs CN¥4.80 in FY 2024) Full year 2025 results: EPS: CN¥5.82 (up from CN¥4.80 in FY 2024). Revenue: CN¥2.58b (up 25% from FY 2024). Net income: CN¥820.6m (up 22% from FY 2024). Profit margin: 32% (in line with FY 2024). Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Feb 10
Now 22% overvalued Over the last 90 days, the stock has fallen 15% to CN¥241. The fair value is estimated to be CN¥198, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 68% in 2 years. Earnings are forecast to grow by 74% in the next 2 years. Announcement • Dec 26
APT Medical Inc. to Report Fiscal Year 2025 Results on Mar 25, 2026 APT Medical Inc. announced that they will report fiscal year 2025 results on Mar 25, 2026 Announcement • Dec 10
APT Medical Inc. (SHSE:688617) announces an Equity Buyback for CNY 250 million worth of its shares. APT Medical Inc. (SHSE:688617) announces a share repurchase program. Under the program, the company will repurchase up to CNY 250 million worth of class A shares. The shares will be repurchased at a price of not more than CNY 315 per share. The shares purchased will be used for the company's employee stock ownership plans or equity incentive plan. Shares not used within 3 years after the completion of the repurchase will be cancelled. The program will be funded out of the company's self-owned funds. The program will be valid till 10 months. Reported Earnings • Oct 25
Third quarter 2025 earnings released: EPS: CN¥1.40 (vs CN¥1.32 in 3Q 2024) Third quarter 2025 results: EPS: CN¥1.40 (up from CN¥1.32 in 3Q 2024). Revenue: CN¥653.6m (up 25% from 3Q 2024). Net income: CN¥198.1m (up 6.8% from 3Q 2024). Profit margin: 30% (down from 35% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 27% per year. Announcement • Sep 30
APT Medical Inc. to Report Q3, 2025 Results on Oct 25, 2025 APT Medical Inc. announced that they will report Q3, 2025 results on Oct 25, 2025 Price Target Changed • Sep 20
Price target increased by 9.1% to CN¥363 Up from CN¥333, the current price target is an average from 5 analysts. New target price is 21% above last closing price of CN¥301. Stock is up 30% over the past year. The company is forecast to post earnings per share of CN¥6.33 for next year compared to CN¥4.80 last year. Buy Or Sell Opportunity • Sep 17
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 11% to CN¥302. The fair value is estimated to be CN¥251, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 32%. Revenue is forecast to grow by 74% in 2 years. Earnings are forecast to grow by 77% in the next 2 years. Buy Or Sell Opportunity • Sep 01
Now 25% overvalued after recent price rise Over the last 90 days, the stock has risen 13% to CN¥305. The fair value is estimated to be CN¥245, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 32%. Revenue is forecast to grow by 74% in 2 years. Earnings are forecast to grow by 77% in the next 2 years. Reported Earnings • Aug 22
Second quarter 2025 earnings released: EPS: CN¥1.72 (vs CN¥1.44 in 2Q 2024) Second quarter 2025 results: EPS: CN¥1.72 (up from CN¥1.44 in 2Q 2024). Revenue: CN¥649.5m (up 19% from 2Q 2024). Net income: CN¥242.0m (up 20% from 2Q 2024). Profit margin: 37% (in line with 2Q 2024). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jun 30
APT Medical Inc. to Report First Half, 2025 Results on Aug 22, 2025 APT Medical Inc. announced that they will report first half, 2025 results on Aug 22, 2025 New Risk • Jun 18
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. Cash payout ratio: 118% Dividend yield: 0.6% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risk Dividend is not well covered by cash flows (118% cash payout ratio). Reported Earnings • Apr 24
First quarter 2025 earnings released: EPS: CN¥1.89 (vs CN¥1.45 in 1Q 2024) First quarter 2025 results: EPS: CN¥1.89 (up from CN¥1.45 in 1Q 2024). Revenue: CN¥564.3m (up 24% from 1Q 2024). Net income: CN¥183.2m (up 31% from 1Q 2024). Profit margin: 33% (up from 31% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 23
APT Medical Inc., Annual General Meeting, May 13, 2025 APT Medical Inc., Annual General Meeting, May 13, 2025, at 13:30 China Standard Time. Location: 22F, Building 20, No. 487, Tianlin Road, Xuhui District, Shanghai China Price Target Changed • Apr 04
Price target increased by 14% to CN¥435 Up from CN¥381, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of CN¥415. Stock is up 39% over the past year. The company is forecast to post earnings per share of CN¥9.51 for next year compared to CN¥6.96 last year. Announcement • Mar 28
APT Medical Inc. to Report Q1, 2025 Results on Apr 23, 2025 APT Medical Inc. announced that they will report Q1, 2025 results on Apr 23, 2025 Reported Earnings • Feb 25
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥6.96 (up from CN¥5.55 in FY 2023). Revenue: CN¥2.07b (up 25% from FY 2023). Net income: CN¥673.5m (up 26% from FY 2023). Profit margin: 33% (in line with FY 2023). Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) also missed analyst estimates by 3.4%. Revenue is forecast to grow 29% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 38% per year whereas the company’s share price has increased by 35% per year. Announcement • Dec 27
APT Medical Inc. to Report Fiscal Year 2024 Results on Apr 23, 2025 APT Medical Inc. announced that they will report fiscal year 2024 results on Apr 23, 2025 Reported Earnings • Oct 26
Third quarter 2024 earnings released: EPS: CN¥1.91 (vs CN¥1.50 in 3Q 2023) Third quarter 2024 results: EPS: CN¥1.91 (up from CN¥1.50 in 3Q 2023). Revenue: CN¥523.9m (up 23% from 3Q 2023). Net income: CN¥185.6m (up 27% from 3Q 2023). Profit margin: 35% (up from 34% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥364, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 19x in the Medical Equipment industry in China. Total returns to shareholders of 44% over the past three years. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (55% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (7.1% average weekly change). Announcement • Sep 30
APT Medical Inc. to Report Q3, 2024 Results on Oct 26, 2024 APT Medical Inc. announced that they will report Q3, 2024 results on Oct 26, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to CN¥409, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 18x in the Medical Equipment industry in China. Total returns to shareholders of 49% over the past three years. Price Target Changed • Sep 20
Price target increased by 9.6% to CN¥376 Up from CN¥343, the current price target is an average from 3 analysts. New target price is 12% above last closing price of CN¥335. Stock is up 31% over the past year. The company is forecast to post earnings per share of CN¥6.69 for next year compared to CN¥5.54 last year. Reported Earnings • Aug 23
Second quarter 2024 earnings released: EPS: CN¥5.46 (vs CN¥1.60 in 2Q 2023) Second quarter 2024 results: EPS: CN¥5.46 (up from CN¥1.60 in 2Q 2023). Revenue: CN¥545.6m (up 25% from 2Q 2023). Net income: CN¥202.4m (up 31% from 2Q 2023). Profit margin: 37% (up from 35% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jul 25
Investor sentiment deteriorates as stock falls 29% After last week's 29% share price decline to CN¥326, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 17x in the Medical Equipment industry in China. Total loss to shareholders of 26% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥339 per share. Announcement • Jun 28
APT Medical Inc. to Report First Half, 2024 Results on Aug 23, 2024 APT Medical Inc. announced that they will report first half, 2024 results on Aug 23, 2024 Announcement • Jun 08
APT Medical Inc., Annual General Meeting, Jun 27, 2024 APT Medical Inc., Annual General Meeting, Jun 27, 2024, at 15:00 China Standard Time. Location: Meeting Room of Hunan Aptmed Medical Equipment Co., Ltd., Changsha, Hunan China Price Target Changed • Apr 30
Price target increased by 10% to CN¥497 Up from CN¥450, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of CN¥504. Stock is up 38% over the past year. The company is forecast to post earnings per share of CN¥9.84 for next year compared to CN¥8.04 last year. Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: CN¥2.10 (vs CN¥1.54 in 1Q 2023) First quarter 2024 results: EPS: CN¥2.10 (up from CN¥1.54 in 1Q 2023). Revenue: CN¥455.3m (up 30% from 1Q 2023). Net income: CN¥140.1m (up 37% from 1Q 2023). Profit margin: 31% (up from 29% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth. Announcement • Apr 17
Shenzhen Mindray Technology Holdings Co., Ltd. completed the acquisition of 19.72% stake in APT Medical Inc. (SHSE:688617) from group of sellers. Shenzhen Mindray Technology Holdings Co., Ltd. agreed to acquire 19.72% stake in APT Medical Inc. (SHSE:688617) from group of sellers for CNY6.2 billion on January 28, 2024. This has been approved by Shenzhen Mindray Bio-Medical Electronics Co., Ltd. 8th directorate during its 5th meeting. This has also been approved by shareholders and directors of SMTH. This is subject for review by Antimonopoly Bureau of the State Administration for Market Regulation (“AB-SAMR”) and confirmation from Shanghai Stock Exchange (“SSE”) Shenzhen Mindray Technology Holdings Co., Ltd. completed the acquisition of 19.72% stake in APT Medical Inc. (SHSE:688617) from group of sellers on April 15, 2024. Major Estimate Revision • Apr 04
Consensus EPS estimates fall by 30% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from CN¥10.27 to CN¥7.17 per share. Revenue forecast steady at CN¥2.22b. Net income forecast to grow 30% next year vs 32% growth forecast for Medical Equipment industry in China. Consensus price target of CN¥427 unchanged from last update. Share price rose 2.5% to CN¥432 over the past week. Announcement • Mar 29
APT Medical Inc. to Report Q1, 2024 Results on Apr 26, 2024 APT Medical Inc. announced that they will report Q1, 2024 results on Apr 26, 2024 Reported Earnings • Mar 25
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: EPS: CN¥8.04 (up from CN¥5.38 in FY 2022). Revenue: CN¥1.65b (up 36% from FY 2022). Net income: CN¥533.9m (up 49% from FY 2022). Profit margin: 32% (up from 29% in FY 2022). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.3%. Revenue is forecast to grow 29% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 24
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: EPS: CN¥8.02 (up from CN¥5.38 in FY 2022). Revenue: CN¥1.65b (up 36% from FY 2022). Net income: CN¥535.6m (up 50% from FY 2022). Profit margin: 32% (up from 29% in FY 2022). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.6%. Revenue is forecast to grow 29% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 07
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥457, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 19x in the Medical Equipment industry in China. Total returns to shareholders of 114% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥223 per share. Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: CN¥2.18 (vs CN¥1.53 in 3Q 2022) Third quarter 2023 results: EPS: CN¥2.18 (up from CN¥1.53 in 3Q 2022). Revenue: CN¥425.7m (up 28% from 3Q 2022). Net income: CN¥145.9m (up 43% from 3Q 2022). Profit margin: 34% (up from 31% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Reported Earnings • Aug 25
Second quarter 2023 earnings released: EPS: CN¥2.32 (vs CN¥1.38 in 2Q 2022) Second quarter 2023 results: EPS: CN¥2.32 (up from CN¥1.38 in 2Q 2022). Revenue: CN¥438.3m (up 51% from 2Q 2022). Net income: CN¥154.7m (up 68% from 2Q 2022). Profit margin: 35% (up from 32% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China. New Risk • Aug 02
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.5% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Reported Earnings • Apr 07
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2022 results: EPS: CN¥5.37 (up from CN¥3.19 in FY 2021). Revenue: CN¥1.22b (up 47% from FY 2021). Net income: CN¥357.4m (up 72% from FY 2021). Profit margin: 29% (up from 25% in FY 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) exceeded analyst estimates by 11%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Medical Equipment industry in China. Reported Earnings • Feb 25
Full year 2022 earnings released: EPS: CN¥5.37 (vs CN¥3.19 in FY 2021) Full year 2022 results: EPS: CN¥5.37 (up from CN¥3.19 in FY 2021). Revenue: CN¥1.22b (up 47% from FY 2021). Net income: CN¥357.4m (up 72% from FY 2021). Profit margin: 29% (up from 25% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Medical Equipment industry in China. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Lijun Xia was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥1.53 (vs CN¥0.71 in 3Q 2021) Third quarter 2022 results: EPS: CN¥1.53 (up from CN¥0.71 in 3Q 2021). Revenue: CN¥331.7m (up 59% from 3Q 2021). Net income: CN¥101.7m (up 116% from 3Q 2021). Profit margin: 31% (up from 23% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in China. Valuation Update With 7 Day Price Move • Oct 14
Investor sentiment improved over the past week After last week's 26% share price gain to CN¥270, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 23x in the Medical Equipment industry in China. Total loss to shareholders of 27% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥233 per share. Valuation Update With 7 Day Price Move • Sep 29
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥217, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 22x in the Medical Equipment industry in China. Total loss to shareholders of 46% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥257 per share. Buying Opportunity • Sep 15
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 7.5%. The fair value is estimated to be CN¥256, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 49% over the last year. Earnings per share has grown by 16%. Revenue is forecast to grow by 96% in 2 years. Earnings is forecast to grow by 96% in the next 2 years. Valuation Update With 7 Day Price Move • Sep 01
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥198, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 22x in the Medical Equipment industry in China. Total loss to shareholders of 37% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥170 per share. Announcement • Jun 15
APT Medical Inc. (SHSE:688617) announces an Equity Buyback for CNY 100 million worth of its shares. APT Medical Inc. (SHSE:688617) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of class A shares. The shares will be repurchased at a price of not more than CNY 270 per share. The shares purchased will be used for the company's employee stock ownership plans or equity incentive plan. The program will be funded out of the company's self-owned funds. The program will be valid till 10 months. Valuation Update With 7 Day Price Move • May 31
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥209, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 23x in the Medical Equipment industry in China. Total loss to shareholders of 41% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥170 per share. Reported Earnings • Apr 29
First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat First quarter 2022 results: EPS: CN¥1.00 (up from CN¥0.77 in 1Q 2021). Revenue: CN¥265.5m (up 65% from 1Q 2021). Net income: CN¥66.8m (up 42% from 1Q 2021). Profit margin: 25% (down from 29% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 4.0%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 51%, compared to a 25% growth forecast for the industry in China. Price Target Changed • Apr 27
Price target decreased to CN¥281 Down from CN¥450, the current price target is an average from 3 analysts. New target price is 84% above last closing price of CN¥153. Stock is down 44% over the past year. The company is forecast to post earnings per share of CN¥5.23 for next year compared to CN¥3.19 last year. Valuation Update With 7 Day Price Move • Apr 11
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥183, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 21x in the Medical Equipment industry in China. Total loss to shareholders of 16% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥171 per share. Valuation Update With 7 Day Price Move • Mar 23
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥225, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 23x in the Medical Equipment industry in China. Total returns to shareholders of 13% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥171 per share. Major Estimate Revision • Mar 15
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate increased from CN¥4.09 to CN¥4.66. Revenue forecast steady at CN¥1.11b. Net income forecast to grow 49% next year vs 32% growth forecast for Medical Equipment industry in China. Consensus price target of CN¥281 unchanged from last update. Share price fell 2.5% to CN¥195 over the past week. Reported Earnings • Feb 27
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: EPS: CN¥3.10 (up from CN¥2.22 in FY 2020). Revenue: CN¥828.7m (up 73% from FY 2020). Net income: CN¥206.6m (up 87% from FY 2020). Profit margin: 25% (up from 23% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.0%. Earnings per share (EPS) missed analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 34%, compared to a 24% growth forecast for the industry in China. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.71 (vs CN¥0.63 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥208.7m (up 61% from 3Q 2020). Net income: CN¥47.2m (up 50% from 3Q 2020). Profit margin: 23% (down from 24% in 3Q 2020). The decrease in margin was driven by higher expenses. Reported Earnings • Aug 25
Second quarter 2021 earnings released: EPS CN¥1.02 (vs CN¥0.63 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥223.9m (up 73% from 2Q 2020). Net income: CN¥67.7m (up 115% from 2Q 2020). Profit margin: 30% (up from 24% in 2Q 2020). The increase in margin was driven by higher revenue. Reported Earnings • Apr 28
First quarter 2021 earnings released: EPS CN¥0.77 (vs CN¥0.43 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥160.8m (up 35% from 1Q 2020). Net income: CN¥47.2m (up 122% from 1Q 2020). Profit margin: 29% (up from 18% in 1Q 2020). The increase in margin was driven by higher revenue. Announcement • Jan 20
APT Medical Inc. to Report Fiscal Year 2020 Results on Apr 27, 2021 APT Medical Inc. announced that they will report fiscal year 2020 results on Apr 27, 2021 
